PerspectivePolicy

Disruptive reproductive technologies

See allHide authors and affiliations

Science Translational Medicine  11 Jan 2017:
Vol. 9, Issue 372, eaag2959
DOI: 10.1126/scitranslmed.aag2959

Article Information

vol. 9 no. 372

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication February 3, 2016
  • Accepted for publication December 18, 2016
  • .

Author Information

  1. I. Glenn Cohen1,*,
  2. George Q. Daley2,3 and
  3. Eli Y. Adashi4
  1. 1Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA 02138, USA.
  2. 2Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115, USA.
  3. 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  4. 4The Warren Alpert Medical School, Brown University, Providence, RI 02906, USA.
  1. *Corresponding author. Email: igcohen{at}law.harvard.edu

Altmetric

Article usage

Article usage: January 2017 to December 2019

AbstractFullPdf
Jan 2017656553431077
Feb 2017709746398
Mar 2017330498165
Apr 2017265379124
May 20171059766519
Jun 2017207226138
Jul 201717424452
Aug 201721520881
Sep 2017282292180
Oct 2017272309110
Nov 2017342361136
Dec 201725534172
Jan 201822329896
Feb 201815227381
Mar 201820137779
Apr 201819830895
May 201818826189
Jun 201815518454
Jul 201810415053
Aug 2018528263
Sep 2018472486
Oct 20187519107
Nov 2018543344
Dec 2018241253
Jan 2019943499
Feb 20191234761
Mar 2019540743
Apr 20193536356
May 20191433770
Jun 20191528435
Jul 2019743219
Aug 2019686630
Sep 2019783855
Oct 20191185593
Nov 2019952522
Dec 201922328

Stay Connected to
   Science Translational Medicine

Navigate This Article